Next-Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients With Lymphoid Malignancies

PURPOSE: Next-generation sequencing (NGS) identifies potentially targetable alterations by US Food and Drug Administration (FDA)–approved drugs and/or by available experimental agents that may not have otherwise been contemplated. Many targeted drugs have been developed for diverse solid cancers; a...

詳細記述

保存先:
書誌詳細
出版年:JCO Precis Oncol
主要な著者: Goodman, Aaron M., Choi, Michael, Wieduwilt, Matthew, Mulroney, Carolyn, Costello, Caitlin, Frampton, Garrett, Miller, Vincent, Kurzrock, Razelle
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2017
主題:
Original Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5495179/
https://ncbi.nlm.nih.gov/pubmed/28681041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.16.00004
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料